In order to promote the whole-course management of portal hypertension, promote the research and translation of diagnosis and monitoring technology, and optimize the practice of precise management of portal hypertension, the "APASL Single Topic Conference 2020 - Portal Hypertension and End Stage Liver Disease" will be held in Guangzhou, China from October 7 to 8, 2020.
The conference was hosted by Asian Pacific Association for the Study of the Liver, and organized by China Foundation for Hepatitis Prevention and Control, the First Hospital of Lanzhou University, Nanfang Hospital and Chinese Portal Hypertension Diagnosis and Monitoring Study Group (CHESS). This conference is one of the highest-level international academic events of portal hypertension held by China. More than 60 overseas and domestic well-known experts will be invited to attend the meeting online and offline to share the latest technology and research results in the field of portal hypertension. The agenda of the conference will cover the early screening and diagnosis, drug treatment, endoscopic treatment, interventional treatment and surgical treatment for portal hypertension and end-stage liver disease.
It is believed that this conference can effectively promote the development of prevention and management of portal hypertension, promote the standardization of multi-disciplinary diagnosis and treatment model, transform the latest diagnosis and treatment technology into clinical practice, and serve patients in a better way.
Looking forward to meeting you in October 2020 in a beautiful flower city, Guangzhou!
Prof. Xiaolong QI
The Asian Pacific Association for the Study of the Liver (APASL)
Chinese Foundation for Hepatitis Prevention and Control (CFHPC)
The First Hospital of Lanzhou University
Nanfang Hospital, Southern Medical University
Chinese Portal Hypertension Diagnosis and Monitoring Study Group (CHESS)
7-8 October, 2020
InterContinental Guangzhou Exhibition Center
Add: 828 Yuejiang Middle Road, HaizhuDistrict，
Guangzhou, Guangdong, 510308, P.R. China